David, one of the original founders of the Company, is a leader in the field of structure based drug design. Following doctoral studies in chemistry at the University at Buffalo, he spent ten years at Merck Sharp and Dohme Research Laboratories, where he directed a variety of drug discovery projects. In 1989, he returned to academia and joined the chemistry faculty at SUNY at Buffalo, where he has had a productive career that has focused on developing protein kinase inhibitors.
David’s expertise has been sought by pharmaceutical and biotechnology companies worldwide, including: Lederle/Wyeth-Ayerst Research Laboratories; New Medical Technologies; Sphinx/Eli Lilly Pharmaceuticals Inc.; Yuhan Corporation; Periodontix, Inc.; ICAgen, Inc.; ARPIDA, Scientific Advisory Board & Founding Scientist; and Signal Pharmaceuticals, Inc. Most notably, he led the chemistry effort at Hypnion, Inc., which was sold to Eli Lilly in 2009 for more than $300 million. The company’s major asset was an insomnia drug that was designed and discovered under the leadership of David.